Free Trial
NASDAQ:BTCY

Biotricity 8/19/2024 Earnings Report

Biotricity logo
$0.40 +0.01 (+2.60%)
As of 02:30 PM Eastern

Biotricity EPS Results

Actual EPS
-$0.49
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Biotricity Revenue Results

Actual Revenue
$3.20 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Biotricity Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Biotricity's next earnings date is estimated for Monday, August 18, 2025, based on past reporting schedules.

Conference Call Resources

Biotricity Earnings Headlines

Biotricity Stock Price History - Investing.com
Biotricity, Inc. (BTCY) - Yahoo Finance
Your Bank Account Is No Longer Safe
What If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what the Department of Justice just admitted in court—claiming cash isn't legally your property. What does that mean? It means Washington thinks they can seize, freeze, or drain your accounts—whenever they want.
See More Biotricity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biotricity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biotricity and other key companies, straight to your email.

About Biotricity

Biotricity (NASDAQ:BTCY) (NASDAQ: BTCY) is a medical technology company specializing in the development and commercialization of remote monitoring solutions for chronic disease management. The company’s core focus is on capturing real-time physiological data to improve patient outcomes, reduce hospital readmissions and support value-based care models. Biotricity’s offerings are designed to bridge the gap between clinical environments and patients’ homes, enabling clinicians to make informed decisions based on continuous biometric feedback.

The company’s flagship product line includes wearable multi-channel ECG monitors, such as the Bioflux® integrated networked biosensor, and the Bioheart® rhythm monitoring service. These FDA-cleared and CE-marked devices transmit encrypted data via cellular or Bluetooth connections to Biotricity’s secure Bioportal® telemedicine platform, where proprietary algorithms analyze heart rate, rhythm abnormalities and other vital signs. In addition to cardiac monitoring, Biotricity has expanded its product suite to include remote respiratory monitoring and wellness solutions tailored to pre-operative, post-operative and chronic care populations.

Founded in Southern California, Biotricity has established a global footprint with headquarters in Newport Beach, California, and research and development facilities in Israel. The company’s remote diagnostics technology has been deployed across the United States and in select international markets, with strategic partnerships in telehealth and clinical research. Biotricity continues to explore cross-border collaborations aimed at integrating its platform into broader digital health ecosystems and value-based reimbursement frameworks.

Biotricity is led by CEO Oded Shraga, whose experience in medical device development and digital health innovation drives the company’s strategic vision. The executive team combines expertise in healthcare technology, regulatory affairs and clinical operations to support ongoing product enhancements, regulatory submissions and market expansion efforts. Through its integrated hardware-software approach, Biotricity aims to set a new standard for remote patient monitoring and telemedicine-enabled care delivery.

View Biotricity Profile

More Earnings Resources from MarketBeat